Pirbuterol

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H526004

CAS#: 38677-81-5 (free base)

Description: Pirbuterol is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma.


Chemical Structure

img
Pirbuterol
CAS# 38677-81-5 (free base)

Theoretical Analysis

Hodoodo Cat#: H526004
Name: Pirbuterol
CAS#: 38677-81-5 (free base)
Chemical Formula: C12H20N2O3
Exact Mass: 240.15
Molecular Weight: 240.300
Elemental Analysis: C, 59.98; H, 8.39; N, 11.66; O, 19.97

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 38029-10-6 (HCl)   38677-81-5 (free base)   65652-44-0 (acetate)    

Synonym: Pirbuterol; Pirbuterolum; Pirbuterolum [INN-Latin]; CP-24,314-14.

IUPAC/Chemical Name: Ethanol, 2-tert-butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)-

InChi Key: VQDBNKDJNJQRDG-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3

SMILES Code: OCC1=C(O)C=CC(C(O)CNC(C)(C)C)=N1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 240.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bonniaud P, Favrolt N, Collet E, Dumas JP, Guilloux L, Pauli G, Camus P. Salbutamol, terbutaline and pirbuterol allergy in an asthmatic patient. Allergy. 2007 Oct;62(10):1219-20. PubMed PMID: 17845596.

2: Derksen FJ, Olszewski M, Robinson NE, Berney C, Lloyd JW, Hakala J, Matson C, Ruth D. Use of a hand-held, metered-dose aerosol delivery device to administer pirbuterol acetate to horses with 'heaves'. Equine Vet J. 1996 Jul;28(4):306-10. PubMed PMID: 8818596.

3: Ashutosh K, Dev G, Steele D. Nonbronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease. Chest. 1995 Jan;107(1):173-8. PubMed PMID: 7813271.

4: Tinkelman DG, Vanden Burgt JA, Ekholm BP. Double-blind, clinical efficacy study comparing 400 micrograms of pirbuterol versus placebo delivered by a breath-actuated aerosol inhaler. J Asthma. 1994;31(3):187-92. PubMed PMID: 7910819.

5: Solé D, Villalba SR, Sestelo MR, Scalabrin DM, Soares FJ, Naspitz CK. Maximum bronchodilator effect of pirbuterol and procaterol administered as sprays with and without an aerochamber. Rev Paul Med. 1993 May-Jun;111(3):397-402. PubMed PMID: 8108632.

6: Bronsky EA, Debelic M, Pujet JC, Hahn M. Ease-of-use study of pirbuterol acetate in the Autohaler actuator in three countries: the United States, Germany, and France. J Asthma. 1993;30(6):439-43. PubMed PMID: 8244913.

7: Derksen FJ, Robinson NE, Berney CE. Aerosol pirbuterol: bronchodilator activity and side effects in ponies with recurrent airway obstruction (heaves). Equine Vet J. 1992 Mar;24(2):107-12. PubMed PMID: 1582387.

8: Dry J, Pradalier A, Michel FB, Pariente R, Boutin C. [Pirbuterol: a new beta 2-sympathomimetic agent. An open multicenter study]. Therapie. 1991 May-Jun;46(3):253-4. French. PubMed PMID: 1792660.

9: Völkl KP, Kroll VM, Wiesemann HG, Schneider B. Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler. Arzneimittelforschung. 1991 May;41(5):533-6. PubMed PMID: 1680327.

10: Bonomi L, Perfetti S, Bellucci R, De Franco I. Ocular hypotensive activity of pirbuterol eye drops in rabbits. J Ocul Pharmacol. 1991 Fall;7(3):191-4. PubMed PMID: 1686050.

11: Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R. A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol. N Z Med J. 1990 Jun 13;103(891):259-61. PubMed PMID: 1972557.

12: Hoffarth HP, Freyberger H, Völkl KP, Ulmer WT. [Inhalation therapy with selective beta 2-sympathomimetic drugs. Effect of pirbuterol administered via the Autohaler and salbutamol administered via the Diskhaler in obstructive respiratory tract disease]. Fortschr Med. 1990 Mar 20;108(8):162-4. German. PubMed PMID: 2186991.

13: Tinkelman DG, Brandon ML, Grieco M, Hudson L, Rosenthal RR, Spector SL, Tashkin D, Votteri B. Comparison of safety and efficacy of inhaled pirbuterol with metaproterenol. Ann Allergy. 1990 Feb;64(2 Pt 2):202-6. PubMed PMID: 2405746.

14: Biernacki W, Prince K, Whyte K, MacNee W, Flenley DC. The effect of six months of daily treatment with the beta-2 agonist oral pirbuterol on pulmonary hemodynamics in patients with chronic hypoxic cor pulmonale receiving long-term oxygen therapy. Am Rev Respir Dis. 1989 Feb;139(2):492-7. PubMed PMID: 2563321.

15: Neilly JB, Carter R, Tweddel A, Martin W, Hutton I, Banham SW, Stevenson RD. Long term haemodynamic, pulmonary function and symptomatic effects of pirbuterol in COPD. Respir Med. 1989 Jan;83(1):59-65. PubMed PMID: 2511610.

16: Chodosh S, Crooks LA, Tuck J. Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy. J Asthma. 1989;26(5):309-15. PubMed PMID: 2484663.

17: Canepa-Anson R, Dawson JR, Kuan P, Poole-Wilson PA, Sutton GC, Cockrill B, Reuben SR. Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure. Br J Clin Pharmacol. 1987 Feb;23(2):173-81. PubMed PMID: 3828194; PubMed Central PMCID: PMC1386065.

18: Nurnberger JI Jr, Kessler L, Simmons-Alling S, Gershon ES. Pirbuterol trial as antidepressant. Biol Psychiatry. 1986 May;21(5-6):565-6. PubMed PMID: 2870743.

19: Uretsky BF, Seecof RM, Reddy PS. The acute hemodynamic response to pirbuterol at rest and exercise in patients with heart failure with observations on long-term response. Can J Cardiol. 1986 Mar-Apr;2(2):80-5. PubMed PMID: 3085906.

20: Mohamed ME, Aboul-Enein HY. Fluorometric and spectrophotometric determination of pirbuterol hydrochloride in authentic and dosage forms. J Assoc Off Anal Chem. 1985 Nov-Dec;68(6):1222-5. PubMed PMID: 4086446.